about
The murine CYLN2 gene: genomic organization, chromosome localization, and comparison to the human gene that is located within the 7q11.23 Williams syndrome critical regionFBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndromeEULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases.Incomplete penetrance of the NOD2 E383K substitution among members of a pediatric granulomatous arthritis pedigree.Rationale, design and baseline data of a mixed methods study examining the clinical impact of a brief transition programme for young people with juvenile idiopathic arthritis: the DON'T RETARD project.Overlap between linear scleroderma, progressive facial hemiatrophy and immune-inflammatory encephalitis in a paediatric cohort.Rhabdomyolysis in diabetic ketoacidosis.The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.Congenital diaphragmatic hernia and chromosome 15q26: determination of a candidate region by use of fluorescent in situ hybridization and array-based comparative genomic hybridizationBlau syndrome, the prototypic auto-inflammatory granulomatous diseaseLong-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice.Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study.Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.Large deletion causing the TSC2-PKD1 contiguous gene syndrome without infantile polycystic diseaseBlau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes.IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.Epilepsy and the immune system: is there a link?Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Dipyridamole enhances ischaemia-induced reactive hyperaemia by increased adenosine receptor stimulation.Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.The EuroSCORE as predictor for prolonged hospital and intensive care stay after cardiac surgery?The cellular composition of the human immune system is shaped by age and cohabitation.NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain.Thoracolumbar intervertebral disc calcifications in an 8-year-old boy: case report and review of the literature.Blau syndrome revisited.Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis.Granulomatous inflammation: The overlap of immune deficiency and inflammation.Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.Recommendations for the management of autoinflammatory diseases.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation CollInflammatory Gene Expression Profile and Defective Interferon-γ and Granzyme K in Natural Killer Cells From Systemic Juvenile Idiopathic Arthritis Patients.Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities.Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options.Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling.What does it mean to grow up with juvenile idiopathic arthritis? A qualitative study on the perspectives of patients.Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis.Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
P50
Q22004256-2A90C934-64B0-4A51-8922-7C15E40E70FEQ28302099-24280554-06F6-47F2-9898-19E0F990970BQ30242006-1700D244-60BD-49A3-A24B-F715EAF3BAD0Q30448460-C9E55E0C-0268-452A-9A01-34DABA326254Q30707232-0876B053-596B-4D6D-B83B-B8EBB9FB0232Q30926191-99AEAD36-F630-402E-832E-CEF86DB6E59FQ33357920-E0BC23B9-C9A9-4E70-9CDD-3B831DAF2C0EQ33377558-EBFBB2D0-5FCD-42F0-94C4-F12B60249167Q33942314-9123BD38-C0FB-42E3-BBF3-59D4FF265737Q34060987-2378F5E8-66A9-4C48-B2C1-8CD84FC429BEQ34157346-42F00731-76B4-4429-8169-AD8CF4378B4AQ34373618-A16BA7B1-04CC-4AA3-BD52-350B33B94672Q34619656-3C54F1B3-D14D-4BD8-AC7F-EA900350F4B8Q34895303-62A7C089-B8A5-4C3C-AA2D-6A95238D3156Q35441572-47B095D8-8A17-4702-84D7-B80F997BA3DDQ35443835-ADEB1F1F-8C13-4520-A3C2-1F3F4702D116Q35935473-B6D4EEEA-8948-4DAE-A99B-678C68C7053DQ36035130-6327E1B5-2379-45FD-A354-16C20F625AE2Q36183846-DF18AB5C-B574-47E5-A540-645EFED0E165Q36510022-7DE43B2C-B5C0-464C-A37F-F742201CC8D4Q36517235-26EAE466-8B45-4215-9CBB-660253520E61Q36813295-1A9CFDDE-B519-4030-AD74-5683F9277E23Q36961446-2096944C-CF32-46FB-9CB5-81D9EA1491D0Q37401815-204AC939-A4BB-44D4-B0F5-A51431FE0A06Q37610858-CE425BB9-A708-44F3-A35F-CB6CB6A00928Q37905511-9E27AFE2-95FF-4D3D-AF5F-6FE6C45A1D36Q38221835-2FCB7C4E-F5F9-4FD8-B832-84E658577FD4Q38224077-9E0AD712-41B8-4EBC-BD42-3C3E5B25FFEDQ38243486-CC40FE53-C434-471C-B2E4-E69061307625Q38281567-E34FEE28-D0A3-4828-896B-6356CF064068Q38537504-2FCB0DDD-7FB2-4DFB-9384-73F512848A50Q38729149-85DC8B9C-DBCC-4F7B-9516-141DC4512C1DQ38742750-973D4EB4-6BD2-4C93-8424-FBB3FF940567Q38855501-40FBB461-04E4-43CC-B954-4A67C967083BQ38862935-41B31090-584B-40C3-B287-48646D8D1853Q39021414-C5BBC2EB-D587-4DB3-846E-E470BB9AEF05Q39883899-812435BE-3A92-48A3-BA48-65E104D96F0AQ40111903-4B99A2F2-9A7B-4F6C-9680-BA54DDEE07F0Q40117209-82EADB46-072B-4680-9923-FA7455C15676Q40198507-66237247-DF5A-4412-B682-4517A4A091A3
P50
description
researcher
@en
wetenschapper
@nl
name
C Wouters
@en
C Wouters
@nl
type
label
C Wouters
@en
C Wouters
@nl
prefLabel
C Wouters
@en
C Wouters
@nl
P106
P31
P496
0000-0002-6426-8845